Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment and Improvements

Equipment and Improvements

6 Months Ended

Jun. 30, 2023

Property, Plant and Equipment [Abstract]


Equipment and Improvements, net
	June 30,		December 31,
	2023		2022
Furniture and office equipment	$	86,930	$	72,692
Lab equipment		153,668		153,668
IT equipment		16,895		16,895
		257,493		243,255
Less: Accumulated Depreciation		170,970		6,723
Total	$	86,523	$	236,532

Depreciation expense for three and six months ended June 30, 2023 was $159,204 and $164,247, respectively and no depreciation expense for the three and six months ended June 30, 2022.